Valsartan, a new angiotensin II antagonist blood pressure reduction in essential hypertension compared with an angiotensin converting enzyme inhibitor, enalapril

Blood Pressure Monitoring

Volumn 2, Issue 3-4, 1997, Pages 179-184

  Mallion, Jean Michel ^a,d   Boutelant, Sophie ^a   Chabaux, Philippe ^b   Baguet, Jean Philippe ^a   Muller, Marie ^c   Meilenbrock, Susanne ^c   Heath, Roger ^c   Bodin, Frédéric ^c  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b Cardiovascular Clinical Development ^*

^c NOVARTIS PHARMA AG   (Switzerland)

^d UNIV GRENOBLE ALPES   (France)

Author keywords

Angiotensin converting enzyme; Angiotensin converting enzyme inhibitors; Angiotensin II receptor antagonist; Enalapril; Essential hypertension; Valsartan

Indexed keywords

ANGIOTENSIN II ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROCHLOROTHIAZIDE; VALSARTAN;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; ESOPHAGITIS; ESSENTIAL HYPERTENSION; EYE DISEASE; FATIGUE; FEMALE; HEADACHE; HEART ARREST; HEART PALPITATION; HOT FLUSH; HUMAN; IMPOTENCE; LIBIDO; MAJOR CLINICAL STUDY; MALE; MICTURITION DISORDER; MULTICENTER STUDY; MUSCLE CRAMP; ORAL DRUG ADMINISTRATION; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; SYSTOLIC BLOOD PRESSURE;

EID: 0030684779     PISSN: 13595237     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. 1993 Guidelines for the management of mild hypertension: memorandum from WHO/ISH meeting. Clin Exp Hypertens 1993, 15:1363-1395.
2. Subcommittee of WHO/ISH Mild Hypertension Liaison Committee: Summary of 1993 World Health Organisation-International Society of Hypertension guidelines for the management of mild hypertension. BMJ 1993, 307:1541-1546.
3. Sever P, Beevers G, Bulpitt C, Lever A, Ramsay L, Reid J, et al.: Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. BMJ 1993, 306:983-987.
4. Boissel J-P, Collet J-P, Lion L, Ducruet T, Moleur P, Luciani J, et al.: A randomized comparison of the effect of four antihypertensive monotherapies on the subjective quality of life in previously untreated asymptomatic patients: field trial in general practice. J Hypertens 1995, 13:1059-1067.
5. Frishman WH, Goldberger J, Sherman D: Enalapril, hydrocholorothiazide, and combination therapy in patients with moderate hypertension. J Clin Hypertens 1987, 3:520-527.
6. Israili ZH, Hall WD: Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. Ann Intern Med 1992, 117:234-242.
7. Webb D, Benjamin N, Collier J, Robinson B: Enalapril induced cough. Lancet 1986, ii:1094.
8. Kaufman MP, Coleridge HM, Coleridge JCG, Baker DG: Bradykinin stimulates afferent vagal C-fibers in intrapulmonary airways of dogs. Am Physiol Soc 1980, 48:511-517.
9. Jammes Y: Tonic sensory pathways of the respiratory system. Eur Resp 1988, 1:176-183.
10. Bork K, Witzke G, Artmann K, Benes P, Böckers M, Kreuz W: Interaction between CI-INA, coagulation, fibrinolysis and kinin system in hereditary angioneurotic edema and urticaria. Arch Dermatol Res 1984, 276:375-380.
11. Foote EF, Halstenson CE: New therapeutic agents in the management of hypertension: angiotensin II receptor antagonists and renin inhibitors. Ann Pharmacother 1993, 27:1495-1503.
12. Weber MA: Clinical experience with the angiotensin II receptor antagonist losartan: a preliminary report Am J Hypertens 1992, 5:2475-2515.
13. Townsend R, Haggert B, Liss C, Edelman JM: Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension. Clin Therap 1995, 17:911-923.
14. Tikkanen I, Omvik P, Jensen HE: Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens 1995, 13:1343-1351.
15. Müller P, Cohen T, de Gasparo M, Sioufi A, Racine-Poon A, Howald H: Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects. Eur J Clin Pharmacol 1994, 47:231-245.
16. Corea L, Cardoni O, Fogari R, Innocenti P, Porcellati C, Provvidenza M, et al.: Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Clin Pharm Ther 1996, 60:341-346.
17. McHugh RB, Le CT. Confidence estimation and size of a clinical trial. Controlled Clin Trials 1984, 5:157-163.
18. Lipsitz L: Orthostatic hypotension in the elderly. N Engl J Med 1989, 321:952-957.